A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalanprednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma

Min Kyoung Kim, Kihyun Kim, Chang Ki Min, Jae Yong Kwak, Sang Byung Bae, Sung Soo Yoon, Je Jung Lee, Ki Hwan Kim, Seung Hyun Nam, Yeung Chul Mun, Hyo Jung Kim, Sung Hwa Bae, Ho Jin Shin, Jung Hee Lee, Joon Seong Park, Seong Hyun Jeong, Mark Hong Lee, Yang Soo Kim, Ho Sup Lee, Keon Woo ParkWon Sik Lee, Sang Min Lee, Jeong Ok Lee, Myung Soo Hyun, Deog Yeon Jo, Sung Nam Lim, Jae Hoon Lee, Do Yeun Cho, Young Rok Do, Jeong A. Kim, Seong Kyu Park, Jin Seok Kim, Soo Jeong Kim, Hawk Kim, Hyeon Gyu Yi, Joon Ho Moon, Chul Won Choi, Sung Hyun Kim, Young Don Joo, Hoon Gu Kim, Byung Soo Kim, Moo Rim Park, Moo Kon Song, Su Youn Kim

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Fingerprint

Dive into the research topics of 'A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalanprednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma'. Together they form a unique fingerprint.

Medicine and Dentistry